Advertisement

Topics

End of Summer Biotech Reading List

21:37 EDT 17 Aug 2017 | Biotech Due Diligence

How Two Common Medications Became One $455 Million Specialty PillMarshall Allen (The Atlantic) The Startling History Behind Merck's New Cancer BlockbusterDavid Shaywitz (Forbes) Conquering HIV’s capsid: After a dozen years, researchers have struck upon a molecule that can disrupt an elusive HIV targetLisa Jarvis (Chemistry & Engineering News) Birth of CRISPR’d pigs advances hopes for turning swine into organ donorsSharon Begley (STAT News) Opinionome: The past [...]

Original Article: End of Summer Biotech Reading List

NEXT ARTICLE

More From BioPortfolio on "End of Summer Biotech Reading List"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...